N--Acetylprocainamide's Antiarrhythmic Action in Patients with Ventricular Tachycardia

Somberg, John; Wynn, Jonathan; Miura, Dennis; Torres, Vilma; Williams, Sharon; Keefe, Deborah
December 1986
Angiology;Dec1986 Part 2, Vol. 37 Issue 12, p972
Academic Journal
Antiarrhythmic properties of N-acetylprocainamide, an active metabolite of procainamide, were studied in 15 patients who presented with a cardiac arrest or documented sustained ventricular tachycardia. Programmed electrical stimulation studies were performed. All patients tested had inducible ventricular tachycardia by programmed electrical stimulation techniques while off all antiarrhythmic therapy. Patients were then tested on procainamide 1000 mg administered intravenously, and ventricular tachycardia could be provoked in 8 of 10 patients. Twenty-four to 36 hours later, N-acetylprocainamide was administered, intravenously, and programmed stimulation was performed after 20 minutes. N-acetylprocainamide did not significantly change heart rate, mean arterial blood pressure, electrocardiographic intervals, A-H or H-V conduction times. N-acetylprocainamide prevented ventricular tachycardia induction in 6 of 15 patients. The mean serum N-acetylprocainamide levels in the group protected was 15.7 �4 �g/ml and 16.2�4 �g/ml the group not protected. These 6 patients were discharged on N-acetylprocainamide 1.5 grams orally every 8 hours. Three patients have been maintained on chronic N-acetylprocainamide every 8 hours. Three patients have been maintained on chronic N-acetylprocainamide therapy (6�2 months), two patients had breakthrough ventricular tachycardia on follow-up Hotter monitoring and alternative therapy was given. N-acetylprocainamide has antiarrhythmic efficacy in preventing induction of ventricular tachycardia by programmed electrical stimulation in a high risk group of patients. On chronic oral therapy, N-acetylprocainamide appears to be well tolerated with antiarrhythmic efficacy that may be enhanced with further upward dose titration.


Related Articles

  • Developing New Anti-Arrhythmics: Clues from the Molecular Basis of Cardiac Ryanodine Receptor (RyR2) Ca2+-Release Channel Dysfunction. George, Christopher H.; Lai, F. Anthony // Current Pharmaceutical Design;Nov2007, Vol. 13 Issue 31, p3195 

    Sudden cardiac death (SCD) remains a major cause of mortality, and despite our knowledge of the causative genetic, molecular and biochemical cellular mechanisms involved, effective therapeutic strategies are lacking. Perturbations in cardiac Ca2+ handling promote arrhythmias and there is...

  • Proarrhythmic Potential of Antimicrobial Agents. Simkó, J.; Csilek, A.; Karászi, J.; Lőrincz, I. // Infection;Jun2008, Vol. 36 Issue 3, p194 

    Several antiarrhythmic and non-cardiovascular drug therapies including antimicrobial agents have been implicated as the causes for QT interval prolongation, torsades de pointes (TdP) ventricular tachycardia and sudden cardiac death. Most of the drugs that have been associated with the...

  • Ventricular Tachycardia and Sudden Cardiac Death. Koplan, Bruce A.; Stevenson, William G. // Mayo Clinic Proceedings;Mar2009, Vol. 84 Issue 3, p289 

    Ventricular tachycardia (VT), which most commonly occurs in patients with structural heart disease, can be associated with an increased risk of sudden death. The most common cause of ventricular fibrillation is acute coronary ischemia, whereas a myocardial scar from prior infarct is the most...

  • Do the spatial characteristics of myocardial scar tissue determine the risk of ventricular arrhythmias? Arenal, Ángel; Hernández, Jesus; Pérez-David, Esther; Rubio-Guivernau, José L.; Ledesma-Carbayo, Maria J.; Fernández-Avilés, Francisco // Cardiovascular Research;May2012, Vol. 94 Issue 2, p324 

    Sudden cardiac death is one of the main causes of mortality in patients with structural heart disease. Although an implantable cardioverter defibrillator significantly reduces the mortality rate, many patients never receive a shock. Identification of high-risk patients would reduce the costs...

  • Pak1 deficiency in cardiomyocytes increases in susceptibility to ventricular arrhythmogenesis in mice. Tsui, H.; Wang, Y.; Liu, W.; Shi, Y.; Wang, R.; Zhang, Y.; Solaro, R.; Ke, Y.; Zhang, H.; Terrar, D.; Cartwright, E.; Wang, X.; Lei, M. // Proceedings of the Physiological Society;2013, p449P 

    50% of mortalities attributable to cardiac causes are accounted for by ventricular tachyarrhythmias occurring either independently or as a result of other underlying heart diseases. Yet, despite the enormity of this problem, the identification of pathophysiological mechanisms contributing to...

  • Treatment of ventricular arrhythmias in the elderly. Aronow, Wilbert S. // Geriatrics;Aug2008, Vol. 63 Issue 8, p20 

    Underlying causes of ventricular tachycardia (VT) or complex ventricular arrhythmias (VA) should be treated if possible. Antiarrhythmic drugs should not be used to treat asymptomatic persons with complex VA and no heart disease. Beta blockers are the only antiarrhythmic drugs that have been...

  • Adverse reactions during treatment with amiodarone hydrochloride. McGovern, Brian; Garan, Hasan; Kelly, Elizabeth; Ruskin, Jeremy N. // British Medical Journal (Clinical Research Edition);7/16/1983, Vol. 287 Issue 6386, p175 

    Investigates on the adverse reactions during treatment with amiodarone hydrochloride. Administration of amiodarone on 80 patients with recurrent cardiac tachyarrhythmias; Treatment of 49 patients for ventricular tachycardia or fibrillation; Side-effects of drugs; Use of antiarrhythmic drugs.

  • Management of Ventricular Arrhythmias in the Elderly. Huffman, Grace Brooke // American Family Physician;01/15/2000, Vol. 61 Issue 2, p535 

    Focuses on a study by W.S. Aronow which recommended against treatment with antiarrhythmic medications in older asymptomatic patients with nonsustained ventricular tachycardia (VT) but without cardiac disease. Principles of treatment for VT; Basis for the diagnosis of VT; Prevalence of...

  • Ventricular tachycardia in patients without apparent... Dale, David C.; Federman, Daniel D. // Cortlandt Forum;12/20/97, Vol. 10 Issue 12, p18 

    Reports that ventricular tachycardia can occur in patients without apparent structural heart disease. Part of the heart where this idiopathic arrythmia generally originates; How to mediate it; How ventricular tachycardia can develop.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics